Contravisory Investment Management Inc. Invests $340,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Contravisory Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 473 shares of the biopharmaceutical company’s stock, valued at approximately $340,000.

A number of other hedge funds have also recently made changes to their positions in the stock. River Street Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% during the 1st quarter. River Street Advisors LLC now owns 474 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 14 shares during the period. Equitable Holdings Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.5% during the 1st quarter. Equitable Holdings Inc. now owns 967 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 14 shares during the period. Colonial River Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.6% during the 4th quarter. Colonial River Wealth Management LLC now owns 341 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 15 shares during the period. Mission Wealth Management LP boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the 1st quarter. Mission Wealth Management LP now owns 435 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 15 shares during the period. Finally, Trifecta Capital Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 25.9% during the 1st quarter. Trifecta Capital Advisors LLC now owns 73 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 15 shares during the period. Hedge funds and other institutional investors own 84.15% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Royal Bank of Canada raised their price target on shares of Regeneron Pharmaceuticals from $820.00 to $830.00 and gave the company a “sector perform” rating in a research report on Monday, August 21st. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $897.00 to $912.00 and gave the stock an “overweight” rating in a research report on Friday, August 4th. StockNews.com began coverage on shares of Regeneron Pharmaceuticals in a research report on Sunday, August 20th. They set a “buy” rating for the company. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $760.00 in a research report on Wednesday, June 28th. Finally, BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $985.00 and gave the stock an “outperform” rating in a research report on Monday, August 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $904.00.

Regeneron Pharmaceuticals Stock Up 0.1 %

REGN stock opened at $824.51 on Tuesday. The company has a market cap of $89.51 billion, a P/E ratio of 21.80, a P/E/G ratio of 2.45 and a beta of 0.19. Regeneron Pharmaceuticals, Inc. has a 52 week low of $668.00 and a 52 week high of $847.50. The company’s 50-day moving average price is $784.26 and its 200 day moving average price is $774.72. The company has a current ratio of 5.45, a quick ratio of 4.64 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $10.24 EPS for the quarter, topping analysts’ consensus estimates of $8.48 by $1.76. Regeneron Pharmaceuticals had a net margin of 33.93% and a return on equity of 19.19%. The firm had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter in the previous year, the firm earned $9.77 earnings per share. The firm’s revenue was up 10.5% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $716.88, for a total transaction of $71,688.00. Following the transaction, the director now owns 18,747 shares of the company’s stock, valued at $13,439,349.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Bonnie L. Bassler sold 853 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $789.00, for a total transaction of $673,017.00. Following the completion of the transaction, the director now owns 1,247 shares of the company’s stock, valued at $983,883. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $716.88, for a total transaction of $71,688.00. Following the completion of the sale, the director now directly owns 18,747 shares of the company’s stock, valued at approximately $13,439,349.36. The disclosure for this sale can be found here. Insiders have sold 32,521 shares of company stock valued at $27,232,176 over the last quarter. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.